Journal of the peripheral nervous system : JPNS · 2026
Trajectory of Recovery and Burden of Residual Symptoms Following Guillain-Barré Syndrome: A Single-Center Prospective Cohort Study From Sri Lanka.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Senanayake Bimsara, Rajaratnam Arun, Thennakoon Thilani, Ekanayake Nimasha, Ruwanpathirana Pramith
Аннотация
BACKGROUND AND AIMS: Guillain-Barré syndrome (GBS) is classically a monophasic illness. In resource-limited settings, patients with GBS are not routinely followed up. However, these patients may suffer from residual symptoms and disability. In this study, we assessed the trajectory of recovery and burden of residual symptoms in patients who developed GBS.
METHODS: This prospective cohort study was conducted at the National Hospital of Sri Lanka from January 1, 2020 to April 1, 2025. We assessed the patients during the illness and then at 1, 3, and 6 months after discharge. The primary outcome was the GBS Disability Score (0 [no disability]-6 [death]), and the secondary outcomes were the individual residual symptoms. All patients with GBS were included. The serial improvement of the GBS Disability Score was assessed using the generalized equation estimate. The burden of residual symptoms was given as percentages.
RESULTS: We included 144 patients with GBS (mean age 46.2 ± 17.3 years; male:female 0.92), and 67 completed the follow-up. There was no in-hospital mortality; one patient (1.5%) died within 6 months. The disability improved significantly, with only 5.9% unable to walk independently at 6 months. Increasing age and axonal variants (AMAN/AMSAN, 37%) were independent negative predictors of recovery. The residual symptoms at 6 months included positive sensory symptoms (42.6%), fatigue (30.9%), and subjective limb weakness (29.4%). Forty-eight percent had to make some change in their occupation.
INTERPRETATION: Although many patients achieve motor recovery, there is a high burden of residual symptoms at 6 months in patients with GBS.
METHODS: This prospective cohort study was conducted at the National Hospital of Sri Lanka from January 1, 2020 to April 1, 2025. We assessed the patients during the illness and then at 1, 3, and 6 months after discharge. The primary outcome was the GBS Disability Score (0 [no disability]-6 [death]), and the secondary outcomes were the individual residual symptoms. All patients with GBS were included. The serial improvement of the GBS Disability Score was assessed using the generalized equation estimate. The burden of residual symptoms was given as percentages.
RESULTS: We included 144 patients with GBS (mean age 46.2 ± 17.3 years; male:female 0.92), and 67 completed the follow-up. There was no in-hospital mortality; one patient (1.5%) died within 6 months. The disability improved significantly, with only 5.9% unable to walk independently at 6 months. Increasing age and axonal variants (AMAN/AMSAN, 37%) were independent negative predictors of recovery. The residual symptoms at 6 months included positive sensory symptoms (42.6%), fatigue (30.9%), and subjective limb weakness (29.4%). Forty-eight percent had to make some change in their occupation.
INTERPRETATION: Although many patients achieve motor recovery, there is a high burden of residual symptoms at 6 months in patients with GBS.